Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M323Revenue (TTM) $M35.2Net Margin (%)-143.2Altman Z-Score-7.2
Enterprise Value $M228EPS (TTM) $-0.6Operating Margin %-144.3Piotroski F-Score4
P/E(ttm)--Beneish M-Score-1.3Pre-tax Margin (%)-143.2Higher ROA y-yY
Price/Book4.410-y EBITDA Growth Rate %--Quick Ratio4.4Cash flow > EarningsN
Price/Sales8.75-y EBITDA Growth Rate %--Current Ratio4.4Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-40.2Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-57.5Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M94.6ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with RIGL

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
RIGLJohn Paulson 2016-03-31 Add0.01%$1.94 - $3.03
($2.48)
$ 3.4138%Add 89.09%999,700
RIGLCharles Brandes 2016-03-31 Sold Out $1.94 - $3.03
($2.48)
$ 3.4138%Sold Out0
RIGLJohn Paulson 2015-12-31 Buy 0.01%$2.53 - $3.55
($3.05)
$ 3.4112%New holding528,700
RIGLCharles Brandes 2015-09-30 Reduce$2.36 - $3.35
($2.98)
$ 3.4114%Reduce -44.07%25,000
RIGLCharles Brandes 2015-03-31 Buy $2.06 - $3.68
($2.74)
$ 3.4124%New holding44,700
RIGLCharles Brandes 2014-09-30 Sold Out $1.97 - $3.84
($2.81)
$ 3.4121%Sold Out0
RIGLCharles Brandes 2014-03-31 Buy $2.7 - $4.75
($3.53)
$ 3.41-3%New holding15,000
RIGLGeorge Soros 2011-12-31 Sold Out -0.0019%$6.68 - $8.3
($7.59)
$ 3.41-55%Sold Out0
RIGLFirst Eagle Investment 2011-06-30 Sold Out $7.11 - $9.19
($8.07)
$ 3.41-58%Sold Out0
RIGLGeorge Soros 2011-06-30 Buy $7.18 - $9.19
($8.08)
$ 3.41-58%New holding14,500
RIGLFirst Eagle Investment 2011-03-31 Buy $6.54 - $7.74
($7.06)
$ 3.41-52%New holding46,700
RIGLGeorge Soros 2010-09-30 Sold Out $6.94 - $8.8
($8.11)
$ 3.41-58%Sold Out0
RIGLGeorge Soros 2010-03-31 Add$7.41 - $9.83
($8.55)
$ 3.41-60%Add 34.29%14,100
RIGLGeorge Soros 2009-12-31 Buy $6.08 - $9.86
($7.86)
$ 3.41-57%New holding10,500
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

RIGL is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


RIGL: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
PAYAN DONALD GEVP, Pres. Discovery&Research 2016-08-30Sell5,303$4-14.75view
PAYAN DONALD GEVP, Pres. Discovery&Research 2015-06-10Sell41,666$3.68-7.34view
PAYAN DONALD GEVP, Pres. Discovery&Research 2015-04-01Sell10,000$3.75-9.07view
VANCE DOLLYEVP Corp. Affairs, G.C., Sect. 2014-12-18Sell1,000$2.2253.6view
VANCE DOLLYEVP Corp. Affairs, G.C., Sect. 2014-12-18Sell1,000$2.2253.6view
PAYAN DONALD GEVP, Pres. Discovery&Research 2014-09-03Sell20,000$2.5633.2view
PAYAN DONALD GEVP, Pres. Discovery&Research 2014-02-24Sell20,000$3.71-8.09view
BVF PARTNERS L P/IL10% Owner 2013-11-19Sell484,622$2.6429.17view
BVF PARTNERS L P/IL10% Owner 2013-06-07Buy32,700$3.47-1.73view
VANCE DOLLYEVP Corp. Affairs, G.C., Sect. 2012-09-13Sell4,151$10.43-67.31view

Quarterly/Annual Reports about RIGL:

News about RIGL:

Articles On GuruFocus.com
Biocept (BIOC) Soars on Liquid Biopsy Appreciation, Rigel Pharmaceuticals (RIGL) Mega-deal with Bris Feb 23 2015 
Rigel Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 01 2011 

More From Other Websites
Rigel Announces Press Release and Conference Call Schedule on Tuesday, August 30, 2016 Sep 17 2016
Rigel's Fostamatinib Meets Primary Endpoint in Phase 3 Study in Chronic ITP Sep 17 2016
Why this Peninsula biotech's layoffs aren't necessarily a bad thing (except for the 46 people losing... Sep 16 2016
Here’s Why These Stocks Are Trending Today Sep 15 2016
RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Costs Associated with Exit or Disposal Activities,... Sep 15 2016
Rigel Restructures to Focus on Fostamatinib Commercialization Sep 15 2016
Rigel Pharmaceuticals cuts 38% of workforce to refocus on fostamatinib Sep 15 2016
Rigel Restructures to Focus on Fostamatinib Commercialization Sep 15 2016
BMO Thinks Rigel's Fostamatinib Market Opportunity Will Be Further Validated Sep 01 2016
ETF’s with exposure to Rigel Pharmaceuticals, Inc. : August 31, 2016 Aug 31 2016
Rigel (RIGL) Stock Up on Positive Phase III Fostamatinib Data Aug 31 2016
Rigel Pharma (RIGL) Stock Jumps on Study Results, Piper Jaffray Ups Price Target Aug 30 2016
What The Latest Data Means For Rigel Pharmaceuticals, Inc. (RIGL) Aug 30 2016
Why Rigel Pharma Is Making a Run Aug 30 2016
Rigel Pharmaceuticals Inc Conference Call to Discuss Its First of Two FIT Phase 3 Results of... Aug 30 2016
Rigel Pharma Claims Late-Stage Study Win for Blood Platelet Drug Aug 30 2016
Rigel's Fostamatinib Meets Primary Endpoint in Phase 3 Study in Chronic ITP Aug 30 2016
RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial... Aug 30 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)